Nvidia shares rise above the 50-day moving average for the second time in three sessions, signaling potential entry point. Nvidia stock approached a buy point after closing above its 50-day moving average on Tuesday, a critical support level. The move marks the second time
SK Hynix Drops 5%, SanDisk Slides 6%, Western Digital Slips 4% as Traders Take Profits in Memory Stocks Quick Read - SK Hynix whipsawed from a 27% Tuesday surge to a 6% Wednesday drop as traders lock in gains, with Micron up 244% YTD. - Western Digital is the mildest decliner...<
Sonic Automotive's market capitalization reaches $2.92 billion Sonic Automotive, Inc. closed at $92.38 per share on July 14, 2026. The company posted a one-month return of 20.54% and a 52-week return of 10.57%. Sonic Automotive is one of the largest auto dealersh
BlackRock Inc (NYSE:BLK) reported second-quarter profit that topped Wall Street estimates on Wednesday, powered by record inflows and higher fees. The world's largest asset manager posted adjusted earnings of $13.91 per share, beating the average analyst estimate of $12.57
This story was To receive daily news and insights, subscribe to our free daily FS Insider. Texas Roadhouse has been one of the final bastions of the anti-delivery movement It's elected instead to focus on to-go, investing in infrastructure, from pickup windows to te
He Took an $18,000 Pay Cut Just to Get Back to Work. Here’s What It Actually Does to His Social Security Quick Read - Social Security uses your 35 highest earning years, so a late-career pay cut rarely affects your benefit if those years are already locked in. - Cla
Cogent Biosciences files NDA for bezuclastinib, targeting rare disease with potential 2026 approval milestone. Cogent Biosciences (NASDAQ:COGT) filed a New Drug Application with the U.S. FDA for bezuclastinib, a treatment for Advanced Systemic Mastocytosis. The submission
Analysts raise TNGX targets to $46 and $60 citing $4 billion revenue opportunity from vopimetostat plus KRAS inhibitors. Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42, maintaining a Buy rating. The firm cited upside potentia
Analyst Alec Stranahan sees 33% upside for BEAM after Prime Medicine arbitration resolves favorably for the company. Bank of America Securities maintained its Buy rating on Beam Therapeutics (NASDAQ:BEAM) and set a $47 price target, implying over 33% upside from current le
PVLA submits initial New Drug Application module for QTORIN, targeting microcystic lymphatic malformations with FDA designations. Palvella Therapeutics (NASDAQ:PVLA) submitted the first module of its New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin anhydrous
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.